COMUNICADO: New Research Shows ACTOS(R) (pioglitazone HCI) is Associated With a 38% Lower Risk of Heart Attack in Type 2 Diabetes (y

 

COMUNICADO: New Research Shows ACTOS(R) (pioglitazone HCI) is Associated With a 38% Lower Risk of Heart Attack in Type 2 Diabetes (y

Actualizado 19/09/2007 16:15:29 CET

(2) T McCall et al. Effects of 30 mg of Pioglitazone vs 4 mg of Rosiglitazone on Hyperglycemia and Dyslipidemia: Results from a Head-to-Head Trial. PS80 / Abstract #0865. Presented at EASD on 19 September, 2007.

(3) Gerrits et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiology and drug safety. 2007. Available online at http://www.interscience.wiley.com. [Last accessed 6 September 2007].

(4) Lincoff et al. Pioglitazone and the risk of cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2007; 298 (10):1216-1218

(5) JA Dormandy et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events) a randomised controlled trial. Lancet. 2005. 366:1279-89.


Contacts:
Alison Wright
Ketchum London
+44-20-7611-3662 (office)
+44-78-3573-4143 (mobile)
Charlotte James
Ketchum London
+44-20-7611-3866 (office)
+44-7771-568-915 (mobile)

Contacts: Alison Wright, Ketchum London, +44-20-7611-3662 (office), +44-78-3573-4143 (mobile); Charlotte James, Ketchum London, +44-20-7611-3866 (office), +44-7771-568-915 (mobile)

Mejora la comunicación de tu empresa con Europa Press Comunicación

Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies